Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov;21(11):1485-1486.
doi: 10.1016/S1473-3099(21)00558-2. Epub 2021 Sep 7.

Hospitalisation among vaccine breakthrough COVID-19 infections

Prerak V Juthani  1 , Akash Gupta  1 , Kelly A Borges  2 , Christina C Price  3 , Alfred I Lee  4 , Christine H Won  5 , Hyung J Chun  6
Affiliations
Comment

Hospitalisation among vaccine breakthrough COVID-19 infections

Prerak V Juthani et al. Lancet Infect Dis. 2021 Nov.

Erratum in

  • Correction to Lancet Infect Dis 2021; 21: 1485-86.
    [No authors listed] [No authors listed] Lancet Infect Dis. 2022 Jan;22(1):e1. doi: 10.1016/S1473-3099(21)00708-8. Epub 2021 Nov 15. Lancet Infect Dis. 2022. PMID: 34793710 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. PVJ, AG, and KAB contributed equally to this Comment. The Yale University institutional review board approved the study (2000027792) and waived the need for informed consent.

Comment on

References

    1. Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00289-9. published online June 23. - DOI - PMC - PubMed
    1. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed
    1. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384:1824–1835. - PMC - PubMed
    1. Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384:1774–1775. - PMC - PubMed

Supplementary concepts